Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study

Comment

Philip A Poole-Wilson et al. Lancet. 2002.

. 2002 Jun 22;359(9324):2199; author reply 2203-4.

doi: 10.1016/S0140-6736(02)09068-2.

No abstract available

Comment on

Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained.
Lubsen J, Hoes A, Grobbee D. Lubsen J, et al. Lancet. 2000 Nov 18;356(9243):1757-9. doi: 10.1016/S0140-6736(00)03215-3. Lancet. 2000. PMID: 11095272
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.